| Chemical Market Reporter |
| January 1, 2001 |
| Phasex Deal is Latest in SCF for Lavipharm. (Lavipharm Laboratories Inc. acquires rights to supercritical fluids technology from Phasex Corp.) |
| LAVIPHARM
LABORATORIES Inc. has acquired exclusive and perpetual rights to Phasex
Corporation’s supercritical fluids (SCF) technology, patents,
trademark and know-how for use in the pharmaceutical and cosmetics
fields. Lavipharm has also
acquired a 30 percent equity stake in Phasex, with the right to purchase
the remainder of the company.
Lavipharm Laboratories is a particle and formulation design company with expertise in molecular transport. Located in East Windsor, N.J., it is the research and development arm of the Lavipharm Group. The Phasex deal caps a busy autumn for Lavipharm. In October, Lavipharm announced plans to buy another SCF business, France-based Separex. |
Copyright 2001 Schnell Publishing Company, Inc. in association with The Gale Group and LookSmart.